Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05783622 is registered in ClinicalTrials.gov with Janux Therapeutics as lead sponsor.

NCT NCT05783622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05783622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
Janux Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 19, 2023
Completion date
October 31, 2026
Enrollment
130 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, non-small cell lung cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, small cell lung cancer, squamous cell carcinoma of the head and neck, triple-negative breast cancer